Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Wen, Jinsheng ^a,b   Elong Ngono, Annie ^a   Angel Regla Nava, Jose ^a   Kim, Kenneth ^a   Gorman, Matthew J ^c   Diamond, Michael S ^c   Shresta, Sujan ^a,b,d  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; DENGUE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ALPHA BETA INTERFERON RECEPTOR; ANTISERUM; EPITOPE; IFNAR1 PROTEIN, MOUSE;

ANTIBODY; CELLS AND CELL COMPONENTS; DENGUE FEVER; IMMUNE RESPONSE; IMMUNITY; PATHOGENICITY; VIRUS; ZIKA VIRUS DISEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BHK-21 CELL LINE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; DENGUE; DENGUE VIRUS; FEMALE; IMMUNIZATION; MALE; MEDIATOR; MOUSE; NONHUMAN; PASSIVE TRANSPORT; SERUM; VIRUS IMMUNITY; VIRUS STRAIN; WILD TYPE; ZIKA FEVER; ZIKA VIRUS; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; TRANSPLANTATION; VIROLOGY;

DENGUE VIRUS; MUS; ZIKA VIRUS;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; DENGUE VIRUS; EPITOPES, T-LYMPHOCYTE; IMMUNE SERA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85033779175     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01669-z     Document Type: Article

References (70)

1. Ioos, S. et al. Current Zika virus epidemiology and recent epidemics. Med. Mal. Infect. 44, 302-307 (2014).
2. Carlson, C. J., Dougherty, E. R. & Getz, W. An ecological assessment of the pandemic threat of Zika virus. PLoS Negl. Trop. Dis. 10, e0004968 (2016).
3. Ikejezie, J. et al. Zika virus transmission-region of the Americas, May 15, 2015-December 15, 2016. Morb. Mortal. Wkly. Rep. 66, 329-334 (2017).
4. Dupont-Rouzeyrol, M. et al. Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. Emerg. Infect. Dis. 2, 381-382 (2015).
5. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
6. Ekins, S. et al. Illustrating and homology modeling the proteins of the Zika virus. F1000Res 5, 275 (2016).
7. Zammarchi, L. et al. Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. J. Clin. Virol. 63, 32-35 (2015).
8. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823-826 (2016).
9. Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. USA 113, 7852-7857 (2016).
10. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102-1108 (2016).
11. Swanstrom, J. A. et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. mBio. 7, e01123-16 (2016).
12. Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175-180 (2017).
13. Rasmussen, S. A. et al. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374, 1981-1987 (2016).
14. Nicastri, E. et al. Zika virus infection in the central nervous system and female genital tract. Emerg. Infect. Dis. 22, 2228-2230 (2016).
15. Tang, W. W. et al. A mouse model of Zika virus sexual transmission and vaginal viral replication. Cell Rep. 17, 3091-3098 (2016).
16. Parra, B. et al. Guillain-barre syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513-1523 (2016).
17. Sharp, T. M. et al. Zika virus infection associated with severe thrombocytopenia. Clin. Infect. Dis. 63, 1198-1201 (2016).
18. Halstead, S. B. Dengue. Lancet 370, 1644-1652 (2007).
19. Guzman, M. G. et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152, 793-799 (2000).
20. Sangkawibha, N. et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120, 653-669 (1984).
21. Tang, W. W., Grewal, R. & Shresta, S. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. Curr. Opin. Virol. 13, 61-66 (2015).
22. Charles, A. S. & Christofferson, R. C. Utility of a dengue-derived monoclonal antibody to enhance Zika infection in vitro. PLoS Curr. 8, 97-98 (2016).
23. Kawiecki, A. B. & Christofferson, R. C. Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro. J. Infect. Dis. 214, 1357-1360 (2016).
24. Butler, D. Brazil asks whether Zika acts alone to cause birth defects. Nature 535, 475-476 (2016).
25. Anderson, K. B. et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl. Trop. Dis. 5, e1311 (2011).
26. Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015).
27. Mongkolsapaya, J. et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9, 921-927 (2003).
28. Mongkolsapaya, J. et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176, 3821-3829 (2006).
29. Imrie, A. et al. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J. Virol. 81, 10081-10091 (2007).
30. + T cells to heterologous serotypes. J. Immunol. 175, 2676-2683 (2005).
31. Screaton, G. et al. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15, 745-759 (2015).
32. Green, S. et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J. Infect. Dis. 180, 1429-1435 (1999).
33. Kurane, I. et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J. Clin. Invest. 88, 1473-1480 (1991).
34. + cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J. Immunol. 154, 1287-1295 (1995).
35. Mathew, A. et al. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J. Clin. Invest. 98, 1684-1691 (1996).
36. + T cells. Proc. Natl. Acad. Sci. USA 110, E2046-E2053 (2013).
37. Weiskopf, D. et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. USA 112, E4256-E4263 (2015).
38. + T cells. Nat. Microbiol. 2, 17036 (2017).
39. + T cell response during primary Zika virus infection in mice. Cell Host Microbe 21, 35-46 (2017).
40. + T cells. J. Immunol. 182, 4865-4873 (2009).
41. Prestwood, T. R. et al. Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J. Virol. 86, 12561-12570 (2012).
42. Elong Ngono, A. et al. Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine 13, 284-293 (2016).
43. + T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J. Virol. 89, 6494-6505 (2015).
44. + T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J. Immunol. 193, 4117-4124 (2014).
45. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720-730 (2016).
46. Kraus, A. A. et al. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45, 3777-3780 (2007).
47. Anderson, K. B. et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209, 360-368 (2014).
48. Reich, N. G. et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J. R. Soc. Interface 10, 20130414 (2013).
49. Snow, G. E. et al. Review article: research on dengue during World War II revisited. Am. J. Trop. Med. Hyg. 91, 1203-1217 (2014).
50. Sabin, A. B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30-50 (1952).
51. Back, A. T. & Lundkvist, A. Dengue viruses-an overview. Infect. Ecol. Epidemiol. 3 doi: 10.3402/iee.v3i0.19839 (2013).
52. Whitehorn, J. & Simmons, C. P. The pathogenesis of dengue. Vaccine 29, 7221-7228 (2011).
53. Wahala, W. M. & Silva, A. M. The human antibody response to dengue virus infection. Viruses 3, 2374-2395 (2011).
54. + T-cell responses. J. Infect. Dis. 214, 1117-1124 (2016).
55. + T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185, 5405-5416 (2010).
56. Zompi, S. et al. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J. Immunol. 188, 404-416 (2012).
57. + T-cell immunity to dengue-lessons for the study of Zika virus. Immunology 150, 146-154 (2017).
58. Durbin, A. P. Dengue antibody and Zika: friend or foe? Trends Immunol. 37, 635-636 (2016).
59. Willis, E. & Hensley, S. E. Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies. Virology 508, 1-6 (2017).
60. Zhang, S. et al. Neutralization mechanism of a highly potent antibody against Zika virus. Nat. Commun. 7, 13679 (2016).
61. Kam, Y. W. et al. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight 2 doi: 10.1172/jci.insight.92428 (2017).
62. Castanha, P. M. S. et al. Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J. Infect. Dis. 215, 781-785 (2017).
63. Paul, L. M. et al. Dengue virus antibodies enhance Zika virus infection. Clin. Transl. Immunol. 5, e117 (2016).
64. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10, e12 (2008).
65. Pierson, T. C. et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-145 (2007).
66. McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus infection in Rhesus macaques. PLoS Pathog. 13, e1006487 (2017).
67. Pantoja, P. et al. Zika virus pathogenesis in Rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).
68. Clark, K. B. et al. Can non-human primates serve as models for investigating dengue disease pathogenesis? Front. Microbiol. 4, 305 (2013).
69. Weiskopf, D. et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. 187, 4268-4279 (2011).
70. + phenotype. J. Virol. 90, 4771-4779 (2016).